Patents by Inventor Alexandre GUY
Alexandre GUY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912645Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.Type: GrantFiled: April 27, 2018Date of Patent: February 27, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, ECOLE NATIONALE VETERINAIRE DE TOULOUSE, UNIVERSITE PAUL SABATIER TOULOUSE III, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Nicolas Cenac, Justine Bertrand-Michel, Teresa Perez-Berezo, Thierry Durand, Jean-Marie Galano, Julien Pujo, Eric Oswald, Patricia Martin, Pauline Le Faouder, Alexandre Guy
-
Publication number: 20230398068Abstract: Pharmaceutical compositions may include chloroquine. More specifically, a pharmaceutical composition comprising chloroquine or pharmaceutically acceptable salt(s) thereof for use in the treatment or prevention of a viral lung infection, preferably caused by Betacoronavirus, including but not limited to 2019-nCoV (coronavirus), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV), wherein the pharmaceutical composition is administered by inhalation. An improved delivery into the lungs of a subject with minimum systemic exposure may be achieved.Type: ApplicationFiled: September 13, 2021Publication date: December 14, 2023Applicant: Philip Morris Products S.A.Inventors: Florian Alexis CALVINO, Philippe Alexandre GUY, Julia HOENG, Aditya Reddy KOLLI, Arkadiusz KUCZAJ, Shoaib MAJEED, Anatoly MAZUROV, Manuel PEITSCH, Tanja ZIVKOVIC SEMREN, Marco VAN DER TOORN
-
Publication number: 20230338285Abstract: A pharmaceutical composition may include hydroxychloroquine or a pharmaceutically acceptable salt thereof, and a solvent. The pharmaceutical composition may include 1 to 400 mg/mL hydroxychloroquine or a pharmaceutically acceptable salt thereof, wherein the solvent is selected from propylene glycol, glycerine, propane-1,3-diol and water or combinations thereof and. The pharmaceutical composition may be suitable for thermal aerosolization. A pharmaceutical composition including hydroxychloroquine or a pharmaceutically acceptable salt thereof may be used in the treatment or prevention of a viral lung infection, wherein the pharmaceutical composition is administered by oral inhalation.Type: ApplicationFiled: September 13, 2021Publication date: October 26, 2023Applicant: Philip Morris Products S.A.Inventors: Florian Alexis CALVINO, Philippe Alexandre GUY, Julia HOENG, Aditya Reddy KOLLI, Arkadiusz KUCZAJ, Shoaib MAJEED, Anatoly MAZUROV, Manuel PEITSCH, Tanja Zivkovic SEMREN, Marco VAN DER TOORN
-
Publication number: 20220304965Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.Type: ApplicationFiled: April 15, 2022Publication date: September 29, 2022Inventors: Nicolas CENAC, Justine BERTRAND-MICHEL, Teresa PEREZ-BEREZO, Thierry DURAND, Jean-Marie GALANO, Julien PUJO, Eric OSWALD, Patricia MARTIN, Pauline LE FAOUDER, Alexandre GUY
-
Publication number: 20200087403Abstract: Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F positive myeloproliferative neo-plasms (MPN). Recent works reported the presence of JAK2V617F in endothelial cells in some MPN patients. Here, the inventors show that JAK2V617F endothelial cells promote thrombosis through induction of endothelial P-selectin expression and thus demonstrate that P-selectin blockade was sufficient to reduce the increased propensity of thrombosis. Accordingly the present invention relates to a method of treating thrombosis in a patient suffering from a myeloproliferative neoplasm comprising administering to the patient a therapeutically effective amount of a P-selectin antagonist.Type: ApplicationFiled: March 14, 2018Publication date: March 19, 2020Inventors: Chloé JAMES, Thierry COUFFINHAL, Virginie GOURDOU-LATYSZENOK, Alexandre GUY, Martine JANDROT-PERRUS
-
Publication number: 20200048187Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.Type: ApplicationFiled: April 27, 2018Publication date: February 13, 2020Inventors: Nicolas CENAC, Justine BERTRAND-MICHEL, Teresa PEREZ-BEREZO, Thierry DURAND, Jean-Marie GALANO, Julien PUJO, Eric OSWALD, Patricia MARTIN, Pauline LE FAOUDER, Alexandre GUY
-
Patent number: 9817003Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-ODE as biomarker.Type: GrantFiled: September 19, 2014Date of Patent: November 14, 2017Assignee: NESTEC S.A.Inventors: Sebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
-
Patent number: 9693942Abstract: The present invention relates generally to the field of enhancing skin appearance. One aspect of the invention aims to provide a composition comprising 4-oxo-2-pentenoic acid for use in the reduction or prevention of regions of the skin with darker pigmentation. The present invention also relates to cosmetic use of a composition comprising 4-oxo-2-pentenoic acid for the reduction or prevention of regions of the skin with darker pigmentation.Type: GrantFiled: March 25, 2013Date of Patent: July 4, 2017Assignee: Nestec S.A.Inventors: Francia Jacqueline Arce Vera, Bertrand Bourqui, Timo Buetler, Stephane Duboux, Francis Foata, Marjorie Guitard, Philippe Alexandre Guy, Nicolas Page, Serge Andre Dominique Rezzi
-
Patent number: 9486425Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to treatment or prevention of liver disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of liver disorders. A further subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of liver disorders linked to an insufficient activity of phase II enzymes in the liver.Type: GrantFiled: March 25, 2013Date of Patent: November 8, 2016Assignee: Nestec S.A.Inventors: Francia Jacqueline Arce Vera, Bertrand Bourqui, Timo Buetler, Stephane Duboux, Francis Foata, Philippe Alexandre Guy, Nicolas Page, Serge Andre Dominique Rezzi
-
Patent number: 9341615Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using PC-O 40:1 as biomarker.Type: GrantFiled: September 19, 2014Date of Patent: May 17, 2016Assignee: NESTEC S.A.Inventors: Sebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
-
Patent number: 9322821Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The invention provides biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose an in vitro method of diagnosing a lifestyle that allows to delay and/or avoid ageing related chronic inflammatory disorders using p-cresol sulphate as biomarker.Type: GrantFiled: September 19, 2014Date of Patent: April 26, 2016Assignee: NESTEC S.A.Inventors: Sebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
-
Patent number: 9261520Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.Type: GrantFiled: November 25, 2014Date of Patent: February 16, 2016Assignee: NESTEC S.A.Inventors: Francois-Pierre Martin, Ivan Montoliu Roura, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
-
Patent number: 9259404Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cognitive decline.Type: GrantFiled: March 25, 2013Date of Patent: February 16, 2016Assignee: Nestec S.A.Inventors: Francia Jacqueline Arce Vera, Bertrand Bourqui, Timo Buetler, Stephane Duboux, Jane Durga, Francis Foata, Philippe Alexandre Guy, Nicolas Page, Serge Andre Dominique Rezzi, Pierre Magistretti, Evelyne Ruchti, Sylvain Lengacher, Igor Allaman
-
Patent number: 9261521Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 42:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.Type: GrantFiled: December 12, 2014Date of Patent: February 16, 2016Assignee: NETSEC S.A.Inventors: Francois-Pierre Martin, Ivan Montoliu Roura, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
-
Patent number: 9238015Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of cardiovascular disorders, for example, atherosclerosis, high blood pressure, coronary heart disease, myocardial infarction, angina pectoris, stroke, and heart failure. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cardiovascular disorders.Type: GrantFiled: March 25, 2013Date of Patent: January 19, 2016Assignee: Nestec S.A.Inventors: Francia Jacqueline Arce Vera, Bertrand Bourqui, Timo Buetler, Stephane Duboux, Francis Foata, Philippe Alexandre Guy, Nicolas Page, Serge Andre Dominique Rezzi
-
Patent number: 9201064Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose an in vitro method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using phenylacetylglutamine (PAG) as biomarker.Type: GrantFiled: September 19, 2014Date of Patent: December 1, 2015Assignee: NESTEC S.A.Inventors: Sebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
-
Patent number: 9201081Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:6 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.Type: GrantFiled: November 25, 2014Date of Patent: December 1, 2015Assignee: NESTEC S.A.Inventors: Francois-Pierre Martin, Ivan Montoliu Roura, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
-
Publication number: 20150147817Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.Type: ApplicationFiled: November 25, 2014Publication date: May 28, 2015Inventors: Francois-Pierre Martin, Ivan Montoliu Roura, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
-
Publication number: 20150105464Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cognitive decline.Type: ApplicationFiled: March 25, 2013Publication date: April 16, 2015Applicant: NESTEC S.A.Inventors: Francia Jacqueline Arce Vera, Bertrand Bourqui, Timo Buetler, Stephane Duboux, Jane Durga, Francis Foata, Philippe Alexandre Guy, Nicolas Page, Serge Andre Dominique Rezzi, Pierre Magistretti, Evelyne Ruchti, Sylvain Lengacher, Igor Allaman
-
Publication number: 20150105296Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker.Type: ApplicationFiled: September 19, 2014Publication date: April 16, 2015Inventors: Sebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi